Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01838395
Recruitment Status : Completed
First Posted : April 24, 2013
Last Update Posted : June 15, 2016
Information provided by (Responsible Party):
BioLineRx, Ltd.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : March 2016
Actual Study Completion Date : June 2016
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 16, 2017
September 14, 2017